Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily

Antiviral Therapy

Volumn 13, Issue 8, 2008, Pages 1087-1090

  van der Flier, Michiel ^a   Verweel, Gwenda ^a   van der Knaap, Linda C ^a   van Jaarsveld, Petronette ^a   Driessen, Gert Jan ^a   van der Lee, Manon ^b   Hartwig, Nico G ^a   Burger, David M ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ABNORMAL LABORATORY RESULT; ADOLESCENT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; CHILD; CHILD CARE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; PILOT STUDY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; TABLET FORMULATION; TREATMENT DURATION; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PYRIMIDINONES; TABLETS;

EID: 58149482072     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Committee for Proprietary Medicinal Products. European Public Assessment Report (EPAR) on Kaletra soft capsules: summary of product characteristics. London: The European Agency for the Evaluation of Medicinal Products; 2001.
2. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIVpositive patients: a 48-week randomized clinical trial. J Infect Dis 2004; 189:265-272.
3. Johnson MA, Gathe JC, Jr, Podzamczer D, et al. A once-daily liponavir/ritonavir-based regimen provides noninferior antiviral activity compared with twice-daily regimen. J Acquir Immune Defic Syndr 2006; 43:153-160.
4. van der Lee M, Verweel G, de Groot R, Burger D. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. Antivir Ther 2006; 11:439-445.
5. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75:7462-7469.
6. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003; 25:393-399.
7. National Institute of Allergy and Infectious Diseases (US), Division of AIDS. Table for grading the severity of adult and pediatric adverse events. Bethseda, MD: NIAID 2004 (Updated 28 December 2004. Accessed 10 August 2008.) Available from http://rcc.tech-res.com/DAIDS%20 RCC%20Forms/ToxicityTables_DAIDS_AE_GradingTable_FinalDec2004.pdf.
8. Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics 2007; 119:e1371-e1383.
9. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003; 22:216-224.